HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy

Neurology. 1999 Feb;52(3):623-5. doi: 10.1212/wnl.52.3.623.

Abstract

Introduction of highly active antiretroviral therapy (HAART) has been associated with many changes in the complications of human immunodeficiency virus (HIV) infection. A cohort of 25 HIV patients with progressive multifocal leukoencephalopathy (PML) treated with HAART experienced a median survival of >46 weeks. This is an improvement in prognosis compared with recent historic experience and correlated with HIV RNA viral load reductions. We conclude that current HIV therapy is important in improving the outlook of PML in the setting of HIV.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Female
  • Humans
  • Leukoencephalopathy, Progressive Multifocal / drug therapy*
  • Leukoencephalopathy, Progressive Multifocal / mortality
  • Male
  • Middle Aged
  • Prognosis
  • Survival Analysis
  • Time Factors

Substances

  • Anti-HIV Agents